Article ID Journal Published Year Pages File Type
10103721 Journal of the American College of Surgeons 2005 11 Pages PDF
Abstract
These results provide additional data to plan clinical trials to answer the question of who can safely avoid CLND after a positive SLN. Patients with minimal tumor burden in the SLN might be the most likely group, although defining “minimal tumor burden” must be standardized. Serial sectioning and immunohistochemistry on the NSLN in any “low-risk” group must be performed in a clinical trial to confirm that residual disease is unlikely before avoiding CLND can be recommended.
Related Topics
Health Sciences Medicine and Dentistry Surgery
Authors
, , , , , , , , , , ,